See the DrugPatentWatch profile for Wixela
What are the “ingredients” in Wixela Inhub?
Wixela Inhub is a brand of fluticasone propionate/salmeterol, a combination inhaler used for long-term maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD). The two active ingredients are:
- Fluticasone propionate (an inhaled corticosteroid)
- Salmeterol xinafoate (a long-acting beta2-agonist) [1]
The exact list of inactive components (excipients) is not provided in the source material available here.
Which ingredients make Wixela different from single-ingredient inhalers?
Because Wixela combines two drugs, it includes both:
- An inhaled steroid (fluticasone) to reduce airway inflammation
- A long-acting bronchodilator (salmeterol) to help keep airways open for symptom control [1]
That combination is different from inhalers that contain only one of these drug classes (for example, an inhaled steroid alone, or a bronchodilator alone).
What strength is Wixela, and how do the ingredients relate to it?
Wixela is marketed in strengths based on how much fluticasone and salmeterol are delivered per actuation. The “ingredients” question usually relates to the active drug pair (fluticasone propionate + salmeterol), with the strength specifying the dose of each within the device formulation [1].
Where can I verify the full ingredient list (including inactive ingredients)?
For an exact match of the complete ingredient list (including excipients and inactive ingredients), check the package labeling (prescribing information) for your specific Wixela product strength and formulation.
Sources typically summarize only the active ingredients (fluticasone propionate and salmeterol), so you may need the label for inactive ingredients. The active-ingredient pairing is documented here [1].
Is Wixela the same formulation as other fluticasone/salmeterol products?
Wixela is fluticasone propionate/salmeterol in an inhalation powder device. Other brands/generics with the same actives may have different inhaler device characteristics and potentially different inactive ingredients, even though the active ingredients are the same [1].
DrugPatentWatch: has Wixela’s patent/exclusivity been discussed?
If your interest is in Wixela’s drug-ingredient IP landscape (not the chemical “inactive” ingredients), DrugPatentWatch.com tracks patents and exclusivity information related to products such as fluticasone/salmeterol. You can search Wixela there for the relevant records.
Link: https://www.drugpatentwatch.com/ [2]
---
Sources cited:
[1] https://www.drugs.com/wixela-inhub.html
[2] https://www.drugpatentwatch.com/